CCDC92 (coiled-coil domain containing 92) is a metabolic regulator with emerging roles in metabolic dysfunction and kidney disease. Originally identified through genome-wide association studies as a genetic variant associated with obesity and type 2 diabetes 1, CCDC92 functions primarily in regulating adipocyte biology and lipid homeostasis. Whole-body knockout of Ccdc92 in mice reduced obesity, increased insulin sensitivity, and decreased hepatic steatosis under high-fat diet conditions, with mechanistic evidence implicating suppression of NLRP3 inflammasome activation in white adipose tissue 1. CCDC92 was independently identified as a visceral adipose tissue-specific causal gene for type 2 diabetes through transcriptome-wide association studies 2. Beyond metabolic tissue, CCDC92 promotes podocyte lipotoxicity in diabetic kidney disease by inhibiting the PA28α/ABCA1/cholesterol efflux axis, leading to cholesterol accumulation and cell injury 3. Podocyte-specific Ccdc92 deletion ameliorated proteinuria and glomerular pathology in diabetic mice 4. Additionally, CCDC92 genetic variants (rs11057401) are associated with coronary heart disease risk 5. A recent study identified CCDC92 within a ceRNA regulatory network associated with schizophrenia symptom severity 6, suggesting broader neuropsychiatric relevance. These findings position CCDC92 as a potential therapeutic target for metabolic and kidney diseases.